The pilot project enrolled children who had a parent simultaneously taking the Diabetes Prevention Program, which has been shown to reduce progression to type 2 diabetes by 59%.
The studies will be done in patients with and without type 2 diabetes.
The analysis followed a landmark study in 2015 that showed insulin sensitivity could improve in patients with type 2 diabetes after only 10 days in a colder climate.
The CVD-REAL study presented at the American College of Cardiology 66th Scientific Session asked whether cardiovascular outcomes seen in the EMPA-REG OUTCOME trial could be seen in a real-world environment, and for the entire class of SGLT2 inhibitors, according to AstraZeneca’s Jim McDermott, PhD, vice president for Medical Affairs, Diabetes.
Results from the CVD-REAL study seek to answer questions raised by the EMPA-REG OUTCOME study: do the effects of SGLT2 inhibitors on heart failure apply to a broad population?


April 12th, 2014
Hershey, PA
May 22nd to 25th , 2014
Fort Lauderdale, FL
August 14th to 16th, 2014
Stowe, VT
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium